newsfilter
← Earnings
Earnings Releases·

Freenome — Third Quarter 2026 Earnings Summary

  • Total revenue surged 17,628% year-over-year to $183.5 million, driven by a $182.5 million license and collaboration milestone from Exact Sciences, resulting in a GAAP net income of $60.1 million versus a $64.5 million loss in 2025.
  • The company reported strong operational cash generation with $35.7 million in free cash flow and $38.4 million in net cash provided by operating activities, while maintaining $430.0 million in cash, equivalents, and marketable securities.
  • Full-year 2026 revenue guidance was set between $192 million and $194 million, with clinical readouts for two single-cancer tests expected in December 2026 and the first multi-cancer detection readout anticipated for mid-2027.
  • Strategic expansion included the U.S. launch of SimpleScreen™ CRC by Abbott on September 30, 2026, and the October 2026 introduction of SimpleScreen™ Lung, alongside the conversion of approximately $50.5 million in convertible notes into equity.
Company
FREENOME INC
Sector
Healthcare
Industry
Diagnostics & Research